APA

Koomen J. V., Heerspink H. J. L., Schrieks I. C., Schwartz G. G., Lincoff A. M., Nicholls S. J., Svensson A., Wedel H., Weichert A., Grobbee D. E. & Stevens J. (20210520). Exposure and response analysis of aleglitazar on cardiovascular risk markers and safety outcomes: An analysis of the AleCardio trial. : Diabetes, obesity & metabolism.

Chicago

Koomen Jeroen V, Heerspink Hiddo J L, Schrieks Ilse C, Schwartz Gregory G, Lincoff A Michael, Nicholls Stephen J, Svensson Anders, Wedel Hans, Weichert Arlette, Grobbee Diederick E and Stevens Jasper. 20210520. Exposure and response analysis of aleglitazar on cardiovascular risk markers and safety outcomes: An analysis of the AleCardio trial. : Diabetes, obesity & metabolism.

Harvard

Koomen J. V., Heerspink H. J. L., Schrieks I. C., Schwartz G. G., Lincoff A. M., Nicholls S. J., Svensson A., Wedel H., Weichert A., Grobbee D. E. and Stevens J. (20210520). Exposure and response analysis of aleglitazar on cardiovascular risk markers and safety outcomes: An analysis of the AleCardio trial. : Diabetes, obesity & metabolism.

MLA

Koomen Jeroen V, Heerspink Hiddo J L, Schrieks Ilse C, Schwartz Gregory G, Lincoff A Michael, Nicholls Stephen J, Svensson Anders, Wedel Hans, Weichert Arlette, Grobbee Diederick E and Stevens Jasper. Exposure and response analysis of aleglitazar on cardiovascular risk markers and safety outcomes: An analysis of the AleCardio trial. : Diabetes, obesity & metabolism. 20210520.